A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.
The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.
When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26.
The results were presented at the International Diabetes Federation (IDF) World Diabetes Congress 2022.
Lori Laffel, Principal Investigator of the DINAMO study and Chief of the Pediatric, Adolescent, and Young Adult Section at the Joslin Diabetes Center and Professor of Pediatrics at Harvard Medical School, said: “These findings are particularly important given the need for more therapeutic options, especially oral agents, to manage type 2 diabetes in young people as, to date, metformin is the only globally available oral treatment for youth.”
Boehringer Ingelheim and Eli Lilly and Company jointly developed the drug as part of the companies’ Alliance centering on compounds representing the largest diabetes treatment classes.
